Last Updated: May 14, 2026

Patent: 10,287,294


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,287,294
Title:Compounds for use in treating or preventing cancerous diseases
Abstract: The invention relates to new compounds of formula (I) that are useful in medicine, specifically in treating or preventing cancerous diseases in a mammal, to pharmaceutical compositions comprising such compounds, optionally together with other pharmaceutically active compounds, or to pharmaceutical formulations comprising such compounds or pharmaceutical compositions. The invention further relates to methods of making these compounds.
Inventor(s): Stellas; Dimitris (Athens, GR), Tamvakopoulos; Constantin (Athens, GR), Klinakis; Apostolos (Iraklio, GR), Efstratiadis; Argiris (Athens, GR), Cournia; Zoe (Kifissia, GR)
Assignee: BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR)
Application Number:15/742,330
Patent Claims:see list of patent claims

Details for Patent 10,287,294

Glossary
Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 January 10, 1978 10,287,294 2036-07-08
Merck Teknika Llc TICE BCG bcg live For Injection 102821 June 21, 1989 10,287,294 2036-07-08
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 June 04, 1986 10,287,294 2036-07-08
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b For Injection 103132 10,287,294 2036-07-08
Merck Sharp & Dohme Llc INTRON A interferon alfa-2b Injection 103132 10,287,294 2036-07-08
Iovance Biotherapeutics Manufacturing Llc PROLEUKIN aldesleukin For Injection 103293 May 05, 1992 10,287,294 2036-07-08
Servier Pharmaceuticals Llc ONCASPAR pegaspargase Injection 103411 February 01, 1994 10,287,294 2036-07-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links